Histotripsy is a precision non-thermal focused ultrasound (FUS) method that mechanically disintegrates tissues. Histotripsy can potentially treat large tumor volumes and induce immune activation towards an anti-tumor immune response.
Histotripsy is an emerging modality for treating multiple cancer types including liver and brain cancer. However, it has not been evaluated for treatment of bone tumors. Canine osteosarcoma (OS) is a primary bone tumor that commonly affects dogs and shares many biologic similarities to human OS. Treatment advances investigated in canine patients have high potential of being translatable to human OS patients. Current standard of care treatment for OS includes surgical resection of the primary tumor via limb amputation or limb-salvage surgery, and chemotherapy for treatment of metastatic disease. Limb-salvage surgery is associated with a high complication rate, and metastasis remains the primary cause of death despite chemotherapeutics. A non- surgical option for treatment of the primary tumor in OS will help canine and human patients preserve their limb and avoid the complications of surgical limb-salvage. A therapy that stimulates an anti-tumor immune response can increase OS survival. This study aims to demonstrate the feasibility of treating OS with histotripsy, optimize the histotripsy treatment strategies for targeting OS, and evaluate the effect of histotripsy on tumor cells, the OS immune microenvironment, as well as the immune profile and clinical outcome of canine OS patients. The results of this study will advance the development of histotripsy as a limb salvage treatment option for primary OS and an immunotherapeutic against metastatic disease for OS.
No reports found.